Orion Oyj Beheer

Beheer criteriumcontroles 2/4

De CEO Orion Oyj's is Liisa Hurme, benoemd in Jan2019, heeft een ambtstermijn van 5.75 jaar. De totale jaarlijkse vergoeding van { bedraagt € 819.50K, bestaande uit 81.6% salaris en 18.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.023% van de aandelen van het bedrijf, ter waarde € 1.58M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.9 jaar en 4.4 jaar.

Belangrijke informatie

Liisa Hurme

Algemeen directeur

€819.5k

Totale compensatie

Percentage CEO-salaris	81.6%
Dienstverband CEO	5.8yrs
Eigendom CEO	0.02%
Management gemiddelde ambtstermijn	1.9yrs
Gemiddelde ambtstermijn bestuur	4.4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Liisa Hurme's beloning veranderd ten opzichte van Orion Oyj's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	€232m
Mar 31 2024	n/a	n/a	€217m
Dec 31 2023	€820k	€668k	€217m
Sep 30 2023	n/a	n/a	€173m
Jun 30 2023	n/a	n/a	€306m
Mar 31 2023	n/a	n/a	€336m
Dec 31 2022	€106k	€106k	€350m

Compensatie versus markt: De totale vergoeding ($USD 912.89K ) Liisa } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 3.65M ).

Compensatie versus inkomsten: De beloning van Liisa is het afgelopen jaar met meer dan 20% gestegen, terwijl de winst van het bedrijf met meer dan 20% is gedaald.

CEO

Liisa Hurme (57 yo)

5.8yrs

Tenure

€819,500

Compensatie

Dr. Liisa Hurme, PhD (Biochemistry), has been President , Chief Executive Officer and Chairman of Managemenbt board at Orion Oyj since Novemnber 01, 2022. Dr. Hurme served as Senior Vice President, Global...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Liisa Hurme	President	5.8yrs	€819.50k	0.023% € 1.5m
Rene Lindell	Chief Financial Officer & Member of Group Executive Management Board	less than a year	geen gegevens	geen gegevens
Olli Huotari	Senior VP of Corporate Functions	22yrs	geen gegevens	0.060% € 3.9m
Satu Ahomäki	Senior VP of Generics and Consumer Health Business Division & Member of the Exe. Mgmt. Board	16.8yrs	geen gegevens	0.025% € 1.6m
Outi Vaarala	Sr. VP of Innovative Medicines	4.3yrs	geen gegevens	0.010% € 671.1k
Juhani Kankaanpaa	Senior VP of Global Operations & Member of Executive Management Board	1.9yrs	geen gegevens	0.0036% € 234.2k
Niclas Lindstedt	Senior VP of Animal Health Business Division & Member of the Exe. Mgmt. Board	1.8yrs	geen gegevens	0.0031% € 200.7k
Hao Pan	Senior VP of the Branded Products Business Division & Member of the Exe. Mgmt. Board	1.8yrs	geen gegevens	0.010% € 682.9k
Julia Macharey	Senior Vice President of People & Culture and Member of Management Board	less than a year	geen gegevens	geen gegevens
Tuukka Hirvonen	Investor Relations & Financial Communications Officer	no data	geen gegevens	geen gegevens
Terhi Ormio	Vice President of Communications	15.5yrs	geen gegevens	geen gegevens
Virve Laitinen	Sr. VP of Corporate Strategy and Program Mgmt. Grp. Level Function & Head of CSPMO	less than a year	geen gegevens	0.023% € 1.5m

1.9yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ORNBVH wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.9 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Mikael Silvennoinen	Independent Director	10.6yrs	€123.40k	0.0069% € 454.6k
Veli-Matti Mattila	Independent Chairman	3.6yrs	€61.40k	0.0066% € 433.0k
Henrik Stenqvist	Director	less than a year	geen gegevens	geen gegevens
Kari Aho	Independent Director	4.4yrs	€61.40k	0.062% € 4.1m
Ari Lehtoranta	Independent Director	7.6yrs	€72.40k	0.0036% € 238.1k
Maziar Doustdar	Independent Director	2.6yrs	€60.80k	0.0011% € 70.9k
Eija Ronkainen	Independent Director	8.6yrs	€61.40k	0.41% € 26.9m
Hilpi Rautelin	Independent Vice Chairman of the Board	7.6yrs	€81.10k	0.0073% € 476.9k
Karen Soerensen	Independent Director	2.6yrs	€66.80k	0.0011% € 70.9k

4.4yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ORNBVH wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.4 jaar).

Orion Oyj Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Orion Oyj, Annual General Meeting, Apr 03, 2025

Orion Corporation Announces Change in Orion Group Executive Management Board as of 31 May 2025

Orion Corporation Announces Appointments to Nomination Committee

Orion Corporation Announces Change in Executive Management Board, Effect as of 1 April 2024

Orion Corporation Announces Board and Committee Appointment

Orion Oyj Announces Retirement of Mikael Silvennoinen as Board Member

Recent updates

Orion Corporation Decides to Terminate the ODM-111 Development Program

Orion Oyj, Annual General Meeting, Apr 03, 2025

Orion Oyj to Report First Half, 2025 Results on Jul 18, 2025

Orion Announces Phase III Aranote Trial of Darolutamide in Combination with Androgen Deprivation Therapy in Men with Metastatic Hormone-Sensitive Prostate Cancer Meets Primary Endpoint

Orion Oyj Revises Earnings Guidance for the Year 2024

Orion Corporation Announces Change in Orion Group Executive Management Board as of 31 May 2025

Orion Corporation Announces Appointments to Nomination Committee

Orion Corporation Announces Change in Executive Management Board, Effect as of 1 April 2024

Orion Corporation Announces Board and Committee Appointment

Orion Oyj Announces Retirement of Mikael Silvennoinen as Board Member

Orion Oyj Announces CFO Changes

Orion Corporation Announces Phase 3 Clinical Trials with ODM-208 (MK-5684) posted to ClinicalTrials.gov Database

Orion Corporation Receives Fda Approval for Bonqat (Pregabalin Oral Solution)

Orion Group Appoints Julia Macharey as Senior Vice President, People & Cultur

Orion Oyj to Report First Half, 2024 Results on Jul 18, 2024

Second quarter 2023 earnings released

Orion Oyj Announces Resignation of Jari Karlson as Chief Financial Officer

First quarter 2023 earnings released

Upcoming dividend of €1.60 per share at 3.7% yield

Insider recently sold €233k worth of stock

Full year 2022 earnings released: EPS: €2.49 (vs €1.38 in FY 2021)

Orion Oyj Provides Earnings Guidance for the Year 2023

Orion Oyj Announces Positive CHMP Opinion for Darolutamide in Combination with Docetaxel for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer

Orion Group Provides Earnings Guidance for the Full Year 2022

Orion Group Appoints Liisa Hurme as CEO, Effective 1 January 2023

Orion Oyj Announces Executive Changes

Orion Announces Approval of Additional Indication of Darolutamide in Combination with Docetaxel for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (Mhspc) from U.S. FDA

Second quarter 2022 earnings released

Orion Oyj to Report Nine Months, 2023 Results on Oct 26, 2023

Orion Oyj to Report Q1, 2023 Results on Apr 27, 2023

Orion Oyj Revises Earnings Guidance for the Full Year 2022

Orion Oyj to Report Q2, 2022 Results on Jul 15, 2022

Orion Oyj (HLSE : ORNBV) acquired V.M.D. n.v./s.a. from Inovet Bv for €130 million.

Orion Oyj (HLSE : ORNBV) acquired V.M.D. n.v./s.a.from Inovet Bv for €130 million.

Orion Oyj Announces Executive Changes

First quarter 2022 earnings released

Orion Oyj Appoints Liisa Hurme as President and the Chair of the Executive Management Board, as of 1 November 2022

Upcoming dividend of €1.50 per share

Orion’S Collaboration Partner Bayer Submits Applications in the U.S. and Eu for Additional Indication of Darolutamide

Investor sentiment improved over the past week

Orion Corporation Announces Results from an Ongoing Phase I/II CYPIDES Trial of ODM-208 Present at ASCO-GU

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Orion Oyj Provides Earnings Outlook for the Year 2022

Orion Announces Arasens Trial with Darolutamide in Combination with Docetaxel and Androgen Deprivation Therapy Meets Primary Endpoint of Significantly Increasing Overall Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Third quarter 2021 earnings released

Second quarter 2021 earnings released: EPS €0.40 (vs €0.54 in 2Q 2020)

Orion Oyj Provides Earnings Guidance for the Year 2021

Orion Oyj Recalls Multivita Forte Dietary Supplement from Consumers

Orion Animal Health’s Tessie® (tasipimidine) Receives Positive CVMP Opinion

Orion Corporation’s Clinical Trial Shows Significant Improvement for Chronic Pain Patients Using Virtual Reality Therapy

Orion Animal Health’s Bonqat® (Pregabalin) Receives Positive CVMP Opinion

First quarter 2021 earnings released: EPS €0.42 (vs €0.48 in 1Q 2020)

Orion Oyj Provides Earnings Guidance for the Year 2021

Upcoming Dividend of €1.50 Per Share

Revenue misses expectations

Full year 2020 earnings released: EPS €1.57 (vs €1.43 in FY 2019)

New 90-day low: €34.16

Full year 2020 earnings released: EPS €1.57 (vs €1.43 in FY 2019)

Revenue misses expectations

New 90-day low: €35.69

Tenax Therapeutics, Inc. Enters into Amendment to License Agreement with Orion Corporation

Orion Is Planning to Renew Its R&D Strategy and Organisation

Orion Oyj to Report First Half, 2021 Results on Jul 19, 2021

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur